TNFR1 expression on cancer cells mediates immune escape and an immunosuppressive microenvironment.

Silencing TNFR1 on tumor cells reduces immune escape by decreasing MDSC recruitment, impairing tumor engraftment in immunocompetent hosts.

• Why it matters: Understanding how tumors evade immune responses is crucial for developing effective therapies, as immune escape mechanisms hinder treatment success in cancer patients.
• What they did: Researchers used CRISPR/Cas9 to knock out TNFR1 in tumor cells and analyzed tumor growth in different mouse models, including immunocompetent and immunodeficient hosts, alongside human tumor cell experiments and transcriptomics.
• The result: TNFR1 knockout variants poorly engrafted in immunocompetent mice due to reduced MDSC infiltration, and human tumor analyses confirmed TNFR1's role in promoting pro-tumor inflammatory mediators, suggesting TNFR1 as a target to counteract immune escape.